Clinical trials: Cholangiocarcinomas
Intrahepatic Cholangiocarcinoma
Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study
This is a single arm, open-label, non-randomized and single-center phase II clinical study, to evaluate the safety, tolerance, and efficacy of Camrelizumab in combination with Apatinib in patients with advanced intrahepatic…
- Trial name
- NCT04454905
- Testing
- Camrelizumab, Apatinib
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Intrahepatic Cholangiocarcinoma (Icc), Hepatic Arterial Infusion Chemotherapy
FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma
This is a prospective, open-label, single-arm phase II study designed to evaluate the efficacy and safety of FOLFOX-based hepatic arterial infusion chemotherapy (HAIC) in combination with donafenib and pucotenlimab as first-line…
- Trial name
- NCT07353827
- Testing
- hepatic arterial infusion chemotherapy (HAIC), Donafenib, Pucotenlimab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sun Yat-sen University
Cholangitis
Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma
The purpose of this study is to determine the effect of normal temperature and 37℃ non-ionic contrast agent acting on ERCP-related cholangeitis after endoscopic retrograde cholangiopancreatography (ERCP) in the treatment of hilar…
- Trial name
- NCT03104569
- Testing
- Injection of 37℃ contrast agent
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Intrahepatic Cholangiocarcinoma
TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma
The objective of this study is to evaluate the efficacy and safety of TACE combined with Tislelizumab in patients with advanced intrahepatic cholangiocarcinoma after progression on first-line systemic therapy.
- Trial name
- NCT04954781
- Testing
- Tislelizumab, TACE
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Extrahepatic Cholangiocarcinoma, Perihilar Cholangiocarcinoma
Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma
Extrahepatic cholangiocarcinoma (eCCA) is a rare and aggressive cancer with poor prognosis. ECCA can be further subcategorised in perihilar and distal cholangiocarcinoma (pCCA and dCCA).
- Conditions
- Extrahepatic Cholangiocarcinoma, Perihilar Cholangiocarcinoma, Distal Cholangiocarcinoma, Resectable
- Trial name
- NEODISCO (NCT06923475)
- Testing
- Pembrolizumab, Gemcitabine, Cisplatin
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- Amsterdam UMC, location VUmc
Liver Neoplasm Malignant Primary, Cholangiocarcinoma
Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors
The investigators design a phase IIB clinical study to explore the efficacy and safety of lenvatinib plus pembrolizumab as a second-line treatment in patients with advanced hepatobiliary malignant tumors and to analyze potential…
- Conditions
- Liver Neoplasm Malignant Primary, Cholangiocarcinoma, Combinational Immunotherapy, Biomarker
- Trial name
- NCT03895970
- Testing
- Lenvatinib plus Pembrolizumab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Peking Union Medical College Hospital
Cholangiocarcinoma, Chondrosarcoma
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced solid tumors, including glioma, that harbor an IDH1 mutation.
- Conditions
- Cholangiocarcinoma, Chondrosarcoma, Glioma, Other Advanced Solid Tumors
- Trial name
- NCT02073994
- Testing
- AG-120
- Where
- 12 sites in United States, France
- Volunteers
- 174 people
- Sponsor
- Institut de Recherches Internationales Servier
Biliary Tract Diseases, Gallbladder Cancer
The Construction of Clinical Database and Multiomics Biobank Based on a Multicentral Prospective Cohort of Benign and Malignant Biliary Tract Diseases
The aim of the study is to establishing a standardized biobank and a clinical information database for patients with benign and malignant tumors of the biliary system.
- Conditions
- Biliary Tract Diseases, Gallbladder Cancer, Extrahepatic Bile Duct Cancer, Intrahepatic Cholangiocarcinoma
- Trial name
- NCT05896956
- Testing
- no interventions
- Volunteers
- 500 people
- Sponsor
- RenJi Hospital
Urachal Cancer, Parathyroid Carcinoma
Agnostic Therapy in Rare Solid Tumors
The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors.
- Conditions
- Urachal Cancer, Parathyroid Carcinoma, Fibrolamellar Carcinoma, Angiosarcoma
- Trial name
- ANTARES (NCT06638931)
- Testing
- Nivolumab
- Where
- 5 sites in Brazil
- Volunteers
- 28 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Malignant Solid Neoplasm, Refractory Cholangiocarcinoma
Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors
This phase II trial studies how well olaparib and ceralasertib (AZD6738) work in treating patients with IDH mutant cholangiocarcinoma or solid tumors.
- Conditions
- Malignant Solid Neoplasm, Refractory Cholangiocarcinoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT03878095
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 13 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Liver Malignant Tumors, Cholangiocarcinoma Metastatic
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
Over the past three decades, the treatment of both primary and secondary liver malignancies has been improved by the development and optimization of multiple minimally invasive thermal ablative therapies.
- Conditions
- Liver Malignant Tumors, Cholangiocarcinoma Metastatic, Pancreatic Cancer, Melanoma
- Trial name
- NCT05053555
- Testing
- high dose rate brachytherapy
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (Icc)
Pragmatic RCT of AI-Assisted Reading for Malignant Hepatic Lesions on CE-CT
The purpose of this multicenter pragmatic randomized controlled trial is to determine whether AI-assisted interpretation of multiphasic liver contrast-enhanced computed tomography (CE-CT) is non-inferior to standard radiology…
- Conditions
- Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (Icc), Hepatic Metastasis, Hepatic Hemangioma
- Trial name
- NCT07768085
- Testing
- AI-assisted abdominal CE-CT reporting, Standard abdominal CE-CT reporting without AI assistance
- Where
- China
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- Shengjing Hospital
Advanced Cholangiocarcinoma
Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma
Cholangiocarcinoma (CCA) is a heterogeneous group of cancers arising from the epithelial cells of bile ducts. Because of highly aggressive malignancy, most of the patients are diagnosed at an advanced stage and lose the chance to…
- Trial name
- NCT05532059
- Testing
- Lenvatinib, tislelizumab, gemcitabine and cisplatin, gemcitabine and cisplatin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Pancreatic Cancer, Periampullary Cancer
Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas
This is a single-center, randomized controlled trial comparing the efficacy of pancreaticojejunostomy with modified N-butyl-2-cyanoacrylate(Glubran® 2) versus standard pancreaticojejunostomy without cyanoacrylate in preventing…
- Conditions
- Pancreatic Cancer, Periampullary Cancer, Duodenal Cancer, Cholangiocarcinoma
- Trial name
- NBCA-MS (NCT07155525)
- Testing
- Pancreaticojejunostomy with Modified N-Butyl-2-Cyanoacrylate (Glubran® 2), Standard(duct-to-mucosa) Pancreaticojejunostomy
- Where
- Egypt
- Volunteers
- 194 people
- Sponsor
- Minia University
Intrahepatic Cholangiocarcinoma (Icc), Neoadjuvant Therapy
Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial
This is a multicenter, single-arm, exploratory clinical study for adults with locally advanced intrahepatic cholangiocarcinoma (ICC) that may be technically resectable but is difficult to remove directly by surgery.
- Trial name
- H-FROG (NCT07847710)
- Testing
- Retlirafusp alfa, Famitinib malate, Gemcitabine & oxaliplatin
- Where
- China
- Volunteers
- 81 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Locally Advanced and Unresectable, But Non-metastatic Pancreatic Adenocarcinoma or Cholangiocarcinoma
Feasibility of Radiotherapy and Concomitant Gemcitabine and Oxaliplatin in Locally Advanced Pancreatic Cancer and Distal Cholangiocarcinoma
The aim of the study is to evaluate the feasibility defined as overall tolerance and toxicity as well as relative dose-intensity and cumulative dose delivered, of an association ofgemcitabine, oxaliplatin and radiotherapy in…
- Trial name
- NCT00286013
- Testing
- Association of gemcitabine, oxaliplatin and radiotherapy
- Where
- 4 sites in Belgium
- Volunteers
- 24 people
- Sponsor
- University Hospital, Ghent
Intrahepatic Cholangiocarcinoma
Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements
The study trial is a open-label, single-arm, multicenter phase II trial investigating the combined treatment of atezolizumab and derazantinib in patients with advanced intrahepatic cholangiocarcinoma with FGFR2…
- Trial name
- NCT05174650
- Testing
- Atezolizumab, Derazantinib
- Where
- 17 sites in Germany
- Volunteers
- 27 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Lung Cancer, Breast Cancer
Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis
The aim of this observational study is to comprehensively analyze the metabolites in plasma samples from multi-cancer patients using advanced mass spectrometry detection technology, in conjunction with metabolomics approaches.
- Conditions
- Lung Cancer, Breast Cancer, Colorectal Cancer, Thyroid Cancer
- Trial name
- NCT06363123
- Where
- 4 sites in China
- Volunteers
- 2,700 people, healthy volunteers welcome
- Sponsor
- Beijing Friendship Hospital
Cancer of the Gallbladder, Cancer of the Biliary Tract
Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma
This is a Phase II trial of the combination of oxaliplatin (Eloxatin) and capecitabine (Xeloda), known as XELOX, in participants with unresectable or recurrent cholangiocarcinoma, including carcinoma of the gallbladder or biliary…
- Trial name
- NCT00338988
- Testing
- Capecitabine, Oxaliplatin
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- M.D. Anderson Cancer Center
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Melanoma Neoplasms
Evaluation of Skin Tests in Biotherapy Allergies
Biotherapies are biological (extracted from an organism or living tissue) or biotechnological drugs used in the treatment of multiple conditions, such as autoimmune inflammatory diseases, cancers, and hematologic diseases.
- Conditions
- Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Melanoma Neoplasms, Small Cell Bronchial Carcinomas, Bronchial Carcinoma
- Trial name
- ETCABIO (NCT06971848)
- Testing
- Drug skin tests (investigating hypersensitivity to a biotherapy)
- Where
- France
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University Hospital, Angers
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.